“A new path in DNA-powered medicine”
Forward Looking Statements

This Presentation contains forward-looking statements with respect to business conducted by Bio-Path Holdings, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially and investors should use their own judgment to evaluate risks.
**DNAbilize™ Technology**

✓ Enables the development and delivery of systemic antisense RNAi nanoparticle treatments for a broad spectrum of cancers including hematological malignancies, solid tumors, as well as diseases outside of cancer

➢ has been the only technology in therapeutic applications that has shown no evidence of toxicity while producing therapeutic effect

➢ has the ability to address hard to treat diseases and unmet clinical needs in fragile populations

✓ **DNAbilize™ is NOT siRNA and is NOT like other antisense technology that have associated toxicity and no delivery**
Investment Highlights

- **Lead candidate prexigebersen in Phase II for acute myeloid leukemia**
- **Second drug candidate being readied for IND to start Phase I**
- **Demonstrated ability to down-regulate target protein in target cells in systemic diseases**
- **Lack of toxicity allows for treatment of fragile populations**
- **UT Southwestern developing clinical and preclinical pipeline for systemic lupus (SLE)**
- **MD Anderson developing clinical and preclinical pipeline in pancreatic, triple negative and inflammatory breast and advanced ovarian cancers**
- **Thomas Jefferson University establishing DNAbilize™ Technology for glioblastoma immunotherapy**
DNAbilize™ Antisense and Technology Profile: A Targeted Method for Treating Disease

- **Antisense RNAi** - a process of interfering with cellular protein production using DNA in a nanoparticle
  - Does not use a toxic agent to kill cells, but blocks production of proteins
  - Advantage of specificity because it targets the disease-causing protein

- **No toxicity** - In numerous animal studies and human patients in prexigebersen clinical trial
  - DNAbilize™ liposome structure is similar to the cellular membrane
  - P-ethoxy DNA does not induce hepatotoxicity or thrombocytopenia

- **Systemic treatment** - I.V. delivery to the main organs via blood flow
- **High cellular uptake** - liposome structure is similar to the cellular membrane
- **Nanoparticle liposomes** - enable penetration into tumors for delivery of drug
- **Proven target inhibition** - demonstrated that DNAbilize™ method inhibits target protein, proving delivery technology works
DNAbilize™ Technology Summary

DNAbilize™ Technology is a proprietary antisense RNAi nanoparticle platform that solves the antisense industry dilemma

**SAFE:** No toxicity from the DNA modification or the lipid nanoparticle delivery, no platelet or hepatic toxicity

**SYSTEMIC:** Allows for systemic distribution via IV infusion

**SPECIFIC:** Knock down a single protein, no off-target effects observed

P-ethoxy backbone  Neutral liposomes  DNAbilize™

![P-ethoxy backbone diagram]

![Neutral liposomes image]

![DNAbilize™ image]
**Clinical Pipeline**

<table>
<thead>
<tr>
<th>Target Indications</th>
<th>Preclinical</th>
<th>IND</th>
<th>Phase I</th>
<th>Phase II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prexigebersen (BP1001)</td>
<td>AML*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prexigebersen (BP1001)</td>
<td>CML*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prexigebersen (BP1001)</td>
<td>Solid tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BP1002 (Liposomal Bcl2)</td>
<td>Lymphoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNAbilize™ Technology</td>
<td>Ready to out-license</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Prexigebersen (BP1001) has received orphan drug designation from the U.S. FDA for AML and CML and from the European Medicines Agency (EMA) for AML*
Continuing Improvement in Product Design and Manufacturing

DNAbilize™ Technology is rapidly being developed into a world class platform employing proprietary antisense RNAi nanoparticle technology
Prexigebersen (BP1001) is an antisense RNAi nanoparticle targeted to the bridging protein Grb2

- Ideal target for myeloid leukemia because it shuts down the Ras pathway in receptor activated myeloid cells without exerting adverse effects on Ras signaling through other channels.
AML, CML, & MDS Patients Refractory or Resistant to Current Therapies

Patients averaged **6 prior therapies**

Dose escalating treatment cycle, 8 doses over 4 weeks, up to 90 mg/m²

**Average reduction in circulating blasts was 67% in patient’s showing anti-leukemic response to drug**

Drug was well tolerated. No DLTs were observed

Of the 18 evaluable patients with circulating blasts, **83% had a response to the drug**
**Prexigebersen Down-regulates Grb2 Protein in Target Cells**

Grb2 levels decreased in 11 of 13 patient samples by end of treatment (EOT). pErk levels decreased in 7 of 13 patient samples by EOT.

<table>
<thead>
<tr>
<th>Subject Number</th>
<th>Cohort</th>
<th>BP1001 dose (mg/m²)</th>
<th>Grb2 Decrease (Day 15)</th>
<th>pErk Decrease (Day 15)</th>
<th>Grb2 Decrease (EOT)</th>
<th>pErk Decrease (EOT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>022</td>
<td>3</td>
<td>20</td>
<td>0%</td>
<td>0%</td>
<td>57%</td>
<td>0%</td>
</tr>
<tr>
<td>023</td>
<td>3</td>
<td>20</td>
<td>0%</td>
<td>3%</td>
<td>28%</td>
<td>45%</td>
</tr>
<tr>
<td>024</td>
<td>3</td>
<td>20</td>
<td>56%</td>
<td>28%</td>
<td>47%</td>
<td>35%</td>
</tr>
<tr>
<td>025</td>
<td>4</td>
<td>40</td>
<td>63%</td>
<td>82%</td>
<td>54%</td>
<td>91%</td>
</tr>
<tr>
<td>026</td>
<td>4</td>
<td>40</td>
<td>47%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>027</td>
<td>4</td>
<td>40</td>
<td>NS¹</td>
<td>NS¹</td>
<td>34%</td>
<td>27%</td>
</tr>
<tr>
<td>028</td>
<td>5</td>
<td>60</td>
<td>0%</td>
<td>0%</td>
<td>30%</td>
<td>54%</td>
</tr>
<tr>
<td>029</td>
<td>5</td>
<td>60</td>
<td>57%</td>
<td>51%</td>
<td>65%²</td>
<td>0%²</td>
</tr>
<tr>
<td>030</td>
<td>5</td>
<td>60</td>
<td>54%</td>
<td>55%</td>
<td>43%</td>
<td>47%</td>
</tr>
<tr>
<td>031</td>
<td>6</td>
<td>90</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>032</td>
<td>6</td>
<td>90</td>
<td>85%</td>
<td>54%</td>
<td>91%</td>
<td>63%</td>
</tr>
<tr>
<td>033</td>
<td>6</td>
<td>90</td>
<td>13%</td>
<td>13%</td>
<td>53%</td>
<td>2%</td>
</tr>
<tr>
<td>034</td>
<td>6</td>
<td>90</td>
<td>42%</td>
<td>42%</td>
<td>40%</td>
<td>0%</td>
</tr>
</tbody>
</table>

NS¹ = no sample collected  
²Fewer cells used in analysis because sample had less cells
Response to Treatment for Blast Crisis CML and Stable Disease in AML

- **Patient 002**: 32 year-old, Hispanic male with myeloid blast crisis of CML

  - Prior therapies consisted of:
    - Gleevec
    - Dasatinib
    - Nilotinib
    - DCC-2036
    - Cytarabine/Fludarabine/
    - Dasatinib/Gemtuzumab
    - PHA-739358
    - Clofarabine/Dasatinib

  - Patient taken off therapy, CNS disease was assumed (not confirmed) and intrathecal Ara-C was administered - patient succumbed due to disease progression prior to going back on treatment

- **Extended Treatment: Patient 006**

  - 54 year-old HIV+ male with AML transformed from Jak2 positive Polycythemia Vera

  - Patient 006 achieved stable disease and marked reduction in peripheral blasts
Safety Segment Phase II Prexigebersen + LDAC Combination Therapy Results

Relapsed/refractory AML patients
- 3 evaluable patients in each of 2 cohorts
- Dose 60 mg/m² and 90 mg/m² respectively
- Received drug 2x week for 4 weeks

5 of 6 patients responded:
- 3 patients achieved complete remission
- 2 patients achieved partial remission

Pharmacokinetics indicate prexigebersen has a 30 hr half life in plasma

No adverse effects attributed to prexigebersen were observed. MTD was not reached.

CR = Complete remission  PR = Partial remission  PD = Progressive disease

<table>
<thead>
<tr>
<th>Patient</th>
<th>BP1001 (mg/m²)</th>
<th>BM Blasts % Reduction</th>
<th>Cycles completed</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>35</td>
<td>60</td>
<td>88</td>
<td>1</td>
<td>CR</td>
</tr>
<tr>
<td>37</td>
<td>60</td>
<td>0</td>
<td>1</td>
<td>PD</td>
</tr>
<tr>
<td>38</td>
<td>60</td>
<td>91</td>
<td>5</td>
<td>CR</td>
</tr>
<tr>
<td>39</td>
<td>90</td>
<td>56</td>
<td>3</td>
<td>PR</td>
</tr>
<tr>
<td>40</td>
<td>90</td>
<td>68</td>
<td>3</td>
<td>CR</td>
</tr>
<tr>
<td>41</td>
<td>90</td>
<td>50</td>
<td>3</td>
<td>PR</td>
</tr>
</tbody>
</table>

71% average reduction of bone marrow blasts in responding patients
Ongoing Phase II Efficacy Trial Design for AML Prexigebersen Combination Therapy

- Safety segment completed, demonstrated no negative synergies but significant efficacy using prexigebersen together with frontline therapy (LDAC)
  - Treatment of de novo AML patients who are induction therapy ineligible and unfit for a stem cell transplant
  - Efficacy trial will be conducted at up to 10 leading cancer centers in the U.S., including the MD Anderson Cancer Center; 6 sites are enrolling and treating patients now

If interim analysis successful, the trial is expected to be rolled into a pivotal trial for accelerated approval
Advances in the CML Program

Presentation at the December 2016 American Society of Hematology Annual Meeting

• *BP1001, a Novel Therapeutic for Chronic Myelogenous Leukemia*
  - Prexigebersen (BP1001) decreased the proliferation of Gleevec® (imatinib)-resistant CML cells in a dose-dependent manner
  - Prexigebersen pretreatment enhanced the inhibitory effects of Sprycel® (dasatinib) in CML cells, leading to cell death
  - Two CML patients in Phase I with drug-resistant mutations showed significant reductions in circulating blasts during treatment, including one patient who went from 89% to 12% while another 24% to 7%

Clinical Program:

• Phase II
  - Determine if there is a dose-limiting toxicity (DLT) of prexigebersen in combination with Sprycel®
  - Two cohorts of three evaluable patients at 60 mg/m² and 90 mg/m²
  - Compare the efficacy of prexigebersen in combination with Sprycel to historical response rates in blast phase and accelerated phase CML patients documented for Sprycel alone in 40 evaluable patients.

*Prexigebersen has the potential to treat the 33% of CML patients who are resistant to Gleevec, the current standard of care*
Prexigebersen Treatment Paradigm

- **Frontline therapy for de novo AML patients who are induction therapy ineligible and unfit for a stem cell transplant**
  - Prexigebersen combination with LDAC
  - Current response rate frontline therapy alone less than 20%
  - Prexigebersen to improve response rates significantly
  - Reduce treatment related mortality

- **Salvage therapy for relapsed and refractory AML patients who have failed two prior regimens**
  - Safety segment trial of prexigebersen combination with LDAC demonstrated complete or partial response in 5 of 6 elderly patients
  - Average patient age 75 years old

- **Blast crisis and accelerated phase CML patients**
  - Prexigebersen combination with frontline therapy
  - Current response rate frontline therapy alone is <30%
  - Average survival 9 months
Preclinical Pipeline

Validating DNAbilize™ with Key Opinion Leaders:

• Establishing prexigebersen in triple negative and inflammatory breast cancer and advanced ovarian cancer with the MD Anderson Cancer Center
  – Advances in liposome properties enhancing solid tumor outcomes

• Developing clinical and preclinical targets for treatment of systemic lupus in collaboration with UT Southwestern Medical Center
  – Stabilizing immune system properties; moving to the next stage

• Developing clinical and preclinical targets in pancreatic cancer using a patient derived *ex vivo* tumor model developed by The MD Anderson Cancer Center
  – Delivery demonstrating the ability to penetrate stroma, the greatest inhibitor to effective pancreatic treatments

• Establishing DNAbilize™ technology for systemic immunotherapy for glioblastoma in collaboration with Thomas Jefferson University
  – Antisense RNAi nanoparticle treatment demonstrating significant advantages versus non-delivery RNAi
Achievements and Upcoming Milestones

☑ Completed safety segment of the Phase II for AML

☑ Enrollment and treating patients in prexigebersen Phase II efficacy trial for AML

☑ Received orphan drug designation in the EU from the European Medicines Agency for AML

☑ Expanded pre-clinical development with new target drug candidates (lymphoma, pancreatic, brain, autoimmune disease)

☑ Expanded solid tumor pre-clinical development of indications for prexigebersen including ovarian, triple negative and inflammatory breast cancer

Value propositions being advanced:

• Enrollment of first 19 patients in Phase II with an interim analysis to be completed with potential for switch to registration trial for accelerated approval

• Estimated completion of the interim analysis by end of 2017

• Safety segment of the prexigebersen Phase II clinical trial for blast and accelerated crisis CML will provide insight into toxicity and potentially efficacy

• Demonstrating effectiveness of DNAbilize™ antisense RNAi nanoparticle technology (broad drug development, licensing opportunities)

• Pursuing new manufacturing and target IP
Leadership

Peter Nielsen  
Co-Founder, President, Chief Executive Officer and Chief Financial Officer  
• Officer and Director since founding Company in 2007  
• Manufacturing development and evolution of engineered product design

William Hahne, M.D.  
Vice President of Clinical Research  
• Medical consultant for Medimmune, Lion Biotechnologies, Seattle Genetics, Aminex Therapeutics, Therakos, and Celgene Cellular Therapeutics  
• Held executive positions in clinical research and medical affairs at Celator Pharmaceuticals, Celsion Corp, and CurGen Corp.

Ana M. Tari, PhD, MBA  
Director, Preclinical Operations & Research  
• Key member of the research team that developed our liposomal delivery technology

Tara Sadeghi, MPH  
Director, Clinical Operations  
• More than 24 years of drug development and clinical operations experience across all phases of clinical development (Phases I through III)

Suzanne Kennedy, PhD  
Director, Corporate Development  
• More than 17 years of marketing, business development, and research & development experience in the biotech industry
Scientific Advisory Board

**Jorge Cortes, M.D.**

*Chairman*

- M.D. from la Facultad de Medicina, Universidad Nacional Autónoma de México
- Jane and John Justin Distinguished Chair in Leukemia Research, Chief of the AML and CML sections, and Deputy Chair of the Department of Leukemia at The University of Texas MDACC
- Has consulted leading pharmaceutical companies such as AstraZeneca on development of prenyltransferase inhibitors, GlaxoSmithKline on the use of topotecan in MDS and CMML, and Rhône-Poulenc Rorer on the use of PEG-Asparaginase in adult ALL

**D. Craig Hooper, Ph.D.**

- Professor of Cancer Biology and Neurological Surgery and the Section Chief for Translational Research, Tumor Division, in the Department of Neurological Surgery at Thomas Jefferson University
- His work has led to novel immune therapies for rabies infection, neuro-inflammation, and cancer with 10 issued U.S. patents and 19 international patents that have been licensed to five companies in the U.S. and abroad
- He is the founding president of the Jefferson Chapter of the National Academy of Inventors and a fellow of the National Academy of Inventors.

*Recruiting additional members*
IP and Financial Snapshot

Intellectual Property

• Original patents licensed from MD Anderson
• New composition and methods of use patents filed to cover DNAbilize™ technology, solely owned by Bio-Path

Financial Snapshot

• **Ticker:** NASDAQ: BPTH
• **Cash:** $6.2 million as of June 30, 2017
  - $10 million registered direct offering and recent $1.65 million warrant exercise extend cash runway through first half of 2018
• **Market Cap:** Approximately $30-40 million
• **Burn rate:**
  - $1 million per quarter core overhead
  - External programs: $0.4-0.8 million per quarter